Table 2 In vitro antifungal susceptibility testing of 243 clinical isolates into 5 antifungal agents

Candida albicans (110)

Amphotericin B

≤0.5 to 1

≤0.5

≤0.5

0^b

Flucytosine

0.5 to > 8

0.5

1

5.5^b

Fluconazole

≤0.125 to 32

0.25

0.5

20.0

Itraconazole

≤0.062 to 4

≤0.062

0.5

28.2^b

Voriconazole

≤0.062 to > 8

≤0.062

0.125

23.6

Candida glabrata (73)

Amphotericin B

≤0.5 to 1

≤0.5

1

0^b

Flucytosine

≤0.062 to > 16

0.125

0.5

2.7^b

Fluconazole

0.25 to> 128

8

32

11.0

Itraconazole

≤0.25 to > 8

2

4

6.8^b

Voriconazole

≤0.062 to > 8

0.25

0.5

6.8^b

Candida tropicalis (37)

Amphotericin B

≤0.5 to 1

≤0.5

1

0^b

Flucytosine

≤0.062 to 4

0.125

0.125

5.4^b

Fluconazole

0.25 to 64

1

2

29.7

Itraconazole

≤0.062 to 64

0.125

0.25

40.5^b

Voriconazole

≤0.062 to > 8

≤0.062

0.125

27.0

Candida krusei (12)

Amphotericin B

≤0.5 to 2

≤0.5

1

0^b

Flucytosine

2 to 8

4

8

0

Fluconazole^a

–

–

–

–

Itraconazole

≤0.062 to 4

0.125

0.5

33.4^b

Voriconazole

≤0.062 to > 8

0.125

0.25

25.0

Candida parapsilosis (5)

Amphotericin B

≤0.5 to 1

0.5

1

0

Flucytosine

≤0.062 to 0.5

0.125

0.25

0

Fluconazole

0.25 to 16

0.5

2

20.0

Itraconazole

≤0.062 to 1

≤0.062

0.125

20.0^b

Voriconazole

≤0.062 to 4

≤0.062

0.125

20.0

Others^c (6)

Amphotericin B

≤0.5 to 1

≤0.5

1

0^b

Flucytosine

≤0.062 to 1

0.25

1

0^b

Fluconazole

0.5 to 64

1

4

16.7^b

Itraconazole

≤0.062 to 0.125

≤0.062

0.125

0^b

Voriconazole

≤0.062 to 0.5

≤0.062

0.125

0^b

All of isolates (243)

Amphotericin B

–

–

–

0

Flucytosine

–

–

–

4.1

Fluconazole^a

–

–

–

18.6

Itraconazole

–

–

–

23.1

Voriconazole

–

–

–

18.5